Related Experiment Video

Updated: Jun 17, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Respiratory syncytial virus vaccine: Is it coming?

Valérie Sales1, Elaine El Wang

  • 1Clinical Development, Aventis Pasteur Ltd, Toronto, Ontario;

Paediatrics & Child Health
|December 19, 2009
PubMed

Insights

Developing a safe and effective respiratory syncytial virus (RSV) vaccine for infants remains challenging. Advances in molecular technologies and protein-based vaccines show promise for early life protection against this common childhood illness.

Area of Science:

  • * Virology and Immunology
  • * Vaccine Development and Pediatric Infectious Diseases

Background:

  • * Respiratory syncytial virus (RSV) is a significant contributor to infant illness and death.
  • * Traditional vaccine approaches for young children face safety and efficacy hurdles.
  • * Molecular technologies are crucial for improving live-attenuated vaccine safety and immunogenicity.

Purpose of the Study:

  • * To review the critical need for an effective RSV vaccine.
  • * To summarize the developmental challenges encountered in creating an RSV vaccine.
  • * To highlight recent progress and promising strategies in RSV vaccine research.

Main Methods:

  • * Review of existing literature on RSV vaccine development.
  • * Analysis of clinical trial data for various vaccine candidates.
  • * Evaluation of molecular technologies impacting vaccine design.

Main Results:

  • * Live-attenuated vaccines require advanced molecular techniques for safety and immunogenicity.
  • * Protein-based vaccines are emerging as viable options.
  • * These vaccines show potential for RSV-primed populations and maternal immunization strategies.

Conclusions:

  • * RSV vaccine development is complex but progressing.
  • * Innovative approaches are essential to protect vulnerable infants.
  • * Protein-based and advanced live-attenuated vaccines offer promising avenues for future prevention.

Keywords:
PaediatricsPreventionRespiratory syncytial virusVaccine

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccinations01:51

Vaccinations

Overview
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...